Pentoxyphilline Versus Stool Therapy in Severe Alcoholic Liver Disease
- Conditions
- Health Condition 1: K701- Alcoholic hepatitisHealth Condition 2: null- Severe Alcoholic Hepatitis
- Registration Number
- CTRI/2016/08/007178
- Lead Sponsor
- Institute of liver and Biliary Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 29
1) All patients with a diagnosis of severe alcoholic hepatitis who are steroid ineligible, are non responders or are intolerant
2) Severe alcoholic hepatitis defined as Maddrey Discriminant Function Score with Serum Bilirubin in mg per dl of more than 32 or a patient of alcoholic hepatitis who presents with any grade of hepatic encephalopathy
3) Conventional therapy defined as oral steroid therapy with 40mg once a day for 7 days.
4) Failure of therapy defined as a Lille Model Score of more than 0.45 at day 8 of steroid therapy OR emergence of complications of steroid therapy or intolerance to steroid protocol or ineligible for steroid therapy.
5) Ineligibility for steroid therapy includes Renal dysfunction, evidence of active sepsis or foci of sepsis, gastro intestinal bleeding and disseminated intravascular coagulation, steroid intolerance, steroid related uncontrolled hyperglycemia which precludes therapy, uncontrolled diabetes mellitus.
6) A Psychologist will be arranged for recipients who are on Fecal Transplant protocol for psychological support throughout the period of one week, during which the transplant procedure will be performed
i) Healthy persons who are willing for faeces donation have to be a close family member
ii) The donor will be required to give a written consent for faeces donation
iii) Once consent is taken, the donor will have to undergo the following screening measures:
a) Clostridium difficile toxins A and B by EIA
b) Routine bacterial culture for enteric pathogens in stool
c) Ova and parasites
d) Blood serology for viruses, human immunodeficiency virus HAV IgM, HBsAg, anti HCV Ab.
1)Active gastrointestinal bleeding
2)Intracranial bleeding
3)Multi-organ failure on mechanical ventilation
4)On high inotropic support
5)Paralytic ileus
6)Pregnancy
7)Sepsis
8)Failure to provide consent
9)Have abnormal bowel motions
10)Have abdominal complaints
11)Have symptoms indicative of irritable bowel syndrome
12)Have extensive travel history or predisposing factors for potentially transmittable diseases
13)Have chronic alcohol intake
14)Have history of substance abuse
15)Are less than 18 years or more than 60 years of age
16)Have HIV and Hepatitis Risk factors
17)Have enteric infections
18)Have inflammatory bowel disease history
19)Have chronic constipation or diarrhea
20)Have prior abdominal surgery or GI neoplasms
21)Have Metabolic Syndrome
22)Have Systemic Autoimmunity
23)Have atopic diseases
24)Have food and respiratory allergies
25)Have any chronic pain syndromes
26)Have chronic Neurologic disorders
27)Have Neurodevelopmental disorders
28)Have had antibiotics for any indication taken within the last 2 months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.